NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
26/04/2025
Voltar para busca
Dado oficial do USPTO
JYMED PEPTIDE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
65
Atualização mais recente
20/05/2025
Tipo de marca
Mista
Classes Nice
5, 35
Data de depósito
17/11/2015
Data de registro
02/04/2019
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/04/2025
Última transação
20/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
704
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
16/08/2014
Primeiro uso no comércio
21/07/2016
Código do desenho
5
Tipo de titular
99
Localização do titular
Shenzhen,Pingshan Dist, CN
Examinador
GARCIA, CLAUDIA
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of stylized letters "JYMED PEPTIDE".
Titulares e representantes
Titulares
Shenzhen JYMed Technology Co., Ltd.
Shenzhen JYMed Technology Co., Ltd.
Representantes
Timothy T. Wang NI WANG & MASSAND PLLC
Classificação técnica
Classes Nice
Classe 5Classe 35
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for human purposes for the treatment of tumor or cancerinflammationdiabetesosteoporosisimmune diseasesdermal diseasescardiovascular diseasescentral nervous system diseasesrespiratory diseases and disordersgastrointestinal diseasesbacterial or fungal infection containing peptides; Pharmaceutical preparations for the treatment of tumor or cancerinflammationdiabetesosteoporosisimmune diseasesdermal diseasescardiovascular diseasescentral nervous system diseasesrespiratory diseases and disordersgastrointestinal diseasesbacterial or fungal infection containing peptides; Drugs for medical purposesdrugs for the treatment of tumor or cancerinflammationdiabetesosteoporosisimmune diseasesdermal diseasescardiovascular diseasescentral nervous system diseasesrespiratory diseases and disordersgastrointestinal diseasesbacterial or fungal infection containing peptides; Active synthetic peptides used for the prevention and treatment of tumor or cancerinflammationdiabetesosteoporosisimmune diseasesdermal diseasescardiovascular diseasescentral nervous system diseasesrespiratory diseases and disordersgastrointestinal diseasesbacterial or fungal infection; Nutritional supplements containing peptides; Veterinary preparationspain relief medication containing peptides; Veterinary preparations for treatment of intestinal bacteriaparasiteinfectious diseasesdigestive system diseaserespiratory diseasereproductive diseases containing peptides; Biological preparations for veterinary purposesfor domestic animals and livestock for the prevention and treatment of infectious diseasesbacterial infectionshypertensioncardiovascular diseaseurinary infectionsrenal diseasereproductive diseases containing peptides; Dietary supplements for animals containing peptides
Classe 35
Advertising; Medical supplies retail store and wholesale distributorship services; Business management and organization consulting; Providing an online market of goods and services for buyers and sellers; Sales promotion for others; Import-export agencies; Retail store and wholesale distributorship services for pharmaceuticalveterinary and sanitary preparations and medical supplies; Systemization of information into computer databases; Drug retail store and wholesale distributorship services; Veterinary drug retail store and wholesale distributorship services
Publicações
Histórico de despachos e eventos da marca no USPTO.
65 publicações encontradas
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
26/04/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
26/04/2025
ES8R
TEAS SECTION 8 RECEIVED
07/11/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/04/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
02/04/2019
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
27/02/2019
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
26/02/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
15/02/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
14/02/2019
IUAF
USE AMENDMENT FILED
24/01/2019
EISU
TEAS STATEMENT OF USE RECEIVED
24/01/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
25/12/2018
TMBN
TTAB RELEASE CASE TO TRADEMARKS
13/11/2018
OP.T
OPPOSITION TERMINATED NO. 999999
13/11/2018
OP.D
OPPOSITION DISMISSED NO. 999999
13/11/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/04/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/04/2018
OP.I
OPPOSITION INSTITUTED NO. 999999
27/02/2018
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
22/11/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/10/2017
PUBO
PUBLISHED FOR OPPOSITION
31/10/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/10/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
26/09/2017
ALIE
ASSIGNED TO LIE
25/09/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/09/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
06/09/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/09/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
06/09/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/09/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/08/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/08/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/08/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/06/2017
GNRT
NON-FINAL ACTION E-MAILED
23/06/2017
CNRT
NON-FINAL ACTION WRITTEN
23/06/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/06/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/06/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/06/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/02/2017
GNRT
NON-FINAL ACTION E-MAILED
27/02/2017
CNRT
NON-FINAL ACTION WRITTEN
27/02/2017
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
17/02/2017
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
07/02/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/01/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
23/01/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
23/01/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
23/01/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
23/01/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/12/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/11/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
30/11/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/10/2016
GNFR
FINAL REFUSAL E-MAILED
12/10/2016
CNFR
FINAL REFUSAL WRITTEN
12/10/2016
DOCK
ASSIGNED TO EXAMINER
14/09/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/09/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/08/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/08/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/03/2016
GNRT
NON-FINAL ACTION E-MAILED
14/03/2016
CNRT
NON-FINAL ACTION WRITTEN
14/03/2016
DOCK
ASSIGNED TO EXAMINER
09/03/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/11/2015
NWAP
NEW APPLICATION ENTERED
20/11/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace JYMED PEPTIDE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.